NCT07689019 Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment
| NCT ID | NCT07689019 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Condition | Head and Neck Cancer (H&N) |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2024-05-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2024-05-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial aims to evaluate whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can reduce treatment-related side effects in patients with head and neck cancer undergoing concurrent chemoradiotherapy. The primary objectives of this study are to determine whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can improve shoulder pain and disability, cervical range of motion, maximum interincisal distance, oral mucositis, systemic inflammation, and chemotherapy-induced nausea and vomiting. Participants will be randomly assigned to one of three groups: Group A will receive standard care (control group); Group B will receive standard care plus transcutaneous electrical nerve stimulation; and Group C will receive standard care plus far infrared radiation therapy combined with transcutaneous electrical nerve stimulation. The intervention will be administered over two cycles of concurrent chemoradiotherapy, for a total of 10 intervention days. During each treatment cycle, participants in the intervention groups will receive the assigned treatment once every morning and once every evening for five consecutive days. Outcome assessments will be performed at three time points during each treatment cycle: before the intervention on Day 1 (baseline), after the intervention on Day 3, and after the intervention on Day 5.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 30 to 85 years. 2. Histologically confirmed head and neck cancer. 3. Scheduled to concurrent chemoradiotherapy. 4. Able to communicate verbally or in writing, willing to complete study questionnaires, and able to comply with all study procedures. Exclusion Criteria: 1. Presence of wounds or skin lesions at the sites where the transcutaneous electrical nerve stimulation electrodes will be applied. 2. Contraindications to transcutaneous electrical nerve stimulation, including a history of epilepsy, brain tumor, arteriovenous malformation, implanted cardiac pacemaker, or implantable cardioverter-defibrillator, due to the potential risk of electrical stimulation interfering with the underlying medical condition.
Frequently Asked Questions
Who can join the NCT07689019 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 85 Years, studying Head and Neck Cancer (H&N). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07689019 currently recruiting?
Yes, NCT07689019 is actively recruiting participants. Visit ClinicalTrials.gov or contact Buddhist Tzu Chi General Hospital to inquire about joining.
Where is the NCT07689019 trial being conducted?
This trial is being conducted at Hualien City, Taiwan.
Who is sponsoring the NCT07689019 clinical trial?
NCT07689019 is sponsored by Buddhist Tzu Chi General Hospital. The trial plans to enroll 102 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.